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Abstract
Background: In humans, N-acetyl L-aspartate (NAA) has not been detected in other tissues than the brain. The physiological 
function of NAA is yet undefined. Recently, it has been suggested that NAA may function as a molecular water pump, 
responsible for the removal of large amounts of water from the human brain. Ovarian tumors typically present as large 
cystic masses with considerable fluid accumulation.
M ethodology and Principal Findings: Using Gas Chromatography-Mass Spectrometry, we demonstrated that NAA was 
present in a high micromolar concentration in oCF of epithelial ovarian tumors (EOTs) of serous histology, sometimes in the 
same range as found in the extracellular space of the human brain. In contrast, oCF of EOTs with a mucinous, endometrioid 
and clear cell histological subtype contained a low micromolar concentration of NAA. Serous EOTs have a cellular 
differentiation pattern which resembles the lining of the fallopian tube and differs from the other histological subtypes. The 
NAA concentration in two samples of fluid accumulation in the fallopian tube (hydrosalpinx) was in the same ranges as NAA 
found in oCF of serous EOTs. The NAA concentration in oCF of patients with serous EOTs was mostly 10 to 50 fold higher 
than their normal serum NAA concentration, whereas in patients with other EOT subtypes, serum and cyst fluid NAA 
concentration was comparable.
ConclusionsandSignificance:The high concentration of NAA in cyst fluid of serous EOTs and low serum concentrations of 
NAA in these patients, suggest a local production of NAA in serous EOTs. Our findings provide the first identification of NAA 
concentrations high enough to suggest local production outside the human brain. Our findings contribute to the ongoing 
research understanding the physiological function of NAA in the human body.
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Introduction
N-acetyl L-aspartate (NAA) is the second most abundant free 
amino acid in the human brain.[1] Neuronal cells contain 
20x10 mmol/L NAA, whereas in the extracellular space of the 
brain, the NAA concentration ranges between 80 and 100 mmol/ 
L.[1] In spite of these high amounts of NAA, its metabolic and 
neurochemical functions remain controversial. NAA is thought to 
function as an important intracellular osmolyte and serve as a 
source of acetate for lipid and myelin synthesis in glia cells. 
Furthermore, NAA is considered to be an intermediate in the 
formation of the neuropeptide N-acetylaspartylgutamate, a storage 
vehicle for neuronal aspartate and glutamate [1-3] Interestingly, a 
patient has been described with a biosynthesis defect of NAA. This
patient had a severe neurological disorder with delayed myelina- 
tion but was still alive at 8 years and 6 months of age.[4]
Recently, it has been proposed that the NAA system functions 
as a molecular water pump (MWP) operating between neurons 
and oligodendrocytes.[5] In contrast to osmolytic transport, 
MWPs are entities that actively use intercompartmental cotrans­
port of water against a gradient.[6] Following this hypothesis, 
NAA is thought to be primarily responsible for the active 
removal of metabolic water from myelinated neurons, of 
which the membranes are known to have a very low water 
permeability.[6]
Concentrations of NAA in body fluid outside the brain are very 
low. In CSF, plasma, and amniotic fluid of healthy individuals, 
mean ± SD (range) concentrations of NAA have been reported to
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be 1.5160.89 (0.25-2.83) mmol/L, 0.4460.20 (0.17-0.84) mmol/ 
L, and 1.2760.74 (0.30-2.55) mmol/L, respectively.[7] Consider­
able amounts of extra-neuronal NAA have been found in the lens 
of the eye and in peritoneal mast cells, although this has never 
been confirmed for humans.[8,9] Using magnetic resonance 
spectroscopy, NAA was shown in detectable amounts in human 
ovarian cyst fluid (oCF).[10,11]
Epithelial ovarian tumors (EOTs) are extremely heterogeneous 
entities which are mostly filled with large amounts of oCF.[12] 
The aim of the present study was to further investigate the 
presence of NAA in oCF from patients with EOTs of different 
histological subtypes. As the mechanism of cyst formation of EOTs 
is still unknown, this study was conducted to better understand the 
possible role of NAA in body water management.
Results
NAA in cyst fluid of epithelial ovarian tumors
The median (25th—75th percentile) NAA concentration in oCF 
of serous, mucinous, endometrioid and clear cell EOTs was 5.1 
(2.9-17.0), 0.6 (0.5-0.8), 1.2 (0.8-4.5), and 1.3 mmol/L, respec­
tively. NAA in serous EOTs was significantly higher compared to 
the other histological subtypes (p<0.001, Kruskal Wallis test). 
The NAA concentration in one third (n = 12) of the serous EOTs 
was more than 10.0 mmol/L. Serous (n = 36) and mucinous 
(n = 23) EOTs could almost perfectly be distinguished by a cut-off 
value of 1.1 mmol/L (Figure 1). All, except one, oCF samples of 
mucinous tumors contained less than 1.1 mmol/L NAA, whereas 
all, except two, oCF samples of serous tumors contained more 
than 1.1 mmol/L NAA (p<0.001, Mann-U Whitney test, 
Figure 1).
NAA in cyst fluid of epithelial ovarian tumors of serous 
histology
In the group of serous EOTs (n = 36), median (25th-75th 
percentile) NAA concentration was 4.9 (3.8-7.3), 1.6 (0.5-14.7), 
and 8.2 (2.9-20.7) mmol/L for malignant (n = 9), borderline 
(n = 3) and benign (n = 24) tumors, respectively. No significant 
differences were found between the groups (p = 0.343, Kruskal- 
Wallis test). In addition, no significant correlation was found 
between the largest diameter of the serous tumors and the NAA 
concentration (p = 0.246, Pearson’s correlation test, data not 
shown).
NAA in cyst fluid of malignant epithelial ovarian tumors
Table 1 summarizes the data of patients with epithelial 
ovarian cancer (n = 25). Endometrioid carcinomas (n = 8) 
showed the largest variation in NAA concentration, ranging 
from 0.07 to 11.8 mmol/L (Table 1). Of the endometrioid 
carcinomas, 4 samples showed an NAA concentration below the 
arbitrary cut-off 1.1 mmol/L. Table 1 also lists the NAA 
concentration of serous (n = 9, range: 1.2-22.8 mmol/L), mucin­
ous (n = 6, range: 0.37-0.80 mmol/L) and clear cell (n = 2, range: 
0.07 and 2.5 mmol/L) ovarian carcinomas. When all carcino­
mas, regardless of subtype, were grouped by FIGO stage, NAA 
concentration in oCF from patients with advanced stage disease 
(stage III and IV, n =  14, median: 4.2, 25th-75th percentile: 1.1­
7.2 mmol/L) was significantly higher than NAA concentration in 
oCF from patients with early stage disease (stage I and II, 
n= 11 , median: 0.8, 25th-75th percentile: 0.5-1.5 mmol/L; 
p = 0.009, Mann U Whitney test). No correlation was found 
between tumor size and NAA concentration (p = 0.612, 
Pearson’s correlation test).
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Figure 1. NAA (mmol/L) concentration of individual patients 
with serous (n = 36) and mucinous (n = 23) tumors. Values are 
presented by dots on a logarithmic scale. A horizontal line represents 
the cut-off value of 1.1 mmol/L NAA. 
doi:10.1371/journal.pone.0010293.g001
NAA concentration in ascites fluid and serum of patients 
with ovarian tumors
The NAA concentration in ascites and corresponding oCF is 
listed in Table 2. Ascites and oCF concentrations of NAA were 
comparable for each patient. Therefore, the concentration of NAA 
in ascites differed between patients with different histological 
subtypes of EOTs as well.
The NAA serum concentration ranged between 0.2 and 
0.8 mmol/L for all patients with ovarian tumors (n = 7, data not 
shown), independent of the histological subtype of the tumor. 
These values are within the reported reference range.[7]
NAA concentration in hepatic cyst fluid and 
hydrosalpingeal fluid
Figure 2 illustrates the boxplots of NAA concentration in oCF of 
ovarian tumors grouped by histological subtype, in hepatic cyst 
fluid and in hydrosalpingeal fluid. The NAA concentration was 
very low in cyst fluid from patients with PCLD (n = 10). The 
median (25th-75th percentile) concentration amounted to 0.6 (0.4— 
0.8) mmol/L and ranged between 0.3 and 0.9 mmol/L. The NAA 
concentration in fluid from the two hydrosalpinges amounted to
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Table 1. NAA (mmol/L) in oCF of patients with serous (n = 9), mucinous (n = 6), endometrioid (n = 8) and clear cell (n = 2) ovarian 
cancer.
Patient no. Histopathological diagnosis FIGO stage Tum or size (cm) NAA (mmol/L)
1 . Serous cystadenocarcinoma IIIc 8 1.2
2 . Serous cystadenocarcinoma Illb 9 4.3
3. Serous cystadenocarcinoma IIIc 9 3.5
4. Serous cystadenocarcinoma IIIc 9 5.1
5. Serous cystadenocarcinoma IV 9 4.1
6. Serous cystadenocarcinoma IV 9 7.6
7. Serous cystadenocarcinoma IIIb 12 4.9
8. Serous cystadenocarcinoma IIIc 18 22.8
9. Serous cystadenocarcinoma IIIc 21 7.0
10 . Mucinous cystadenocarcinoma IIIb 10 0.68
1 1 . Mucinous cystadenocarcinoma IIIb 13 0.80
1 2 . Mucinous cystadenocarcinoma Ic 17 0.37
13. Mucinous cystadenocarcinoma Ia 18 0.52
14. Mucinous cystadenocarcinoma IIIa 20 0.33
15. Mucinous cystadenocarcinoma Ic 26 0.50
16. Endometrioid cystadenocarcinoma IIb 4 0.8
17. Endometrioid cystadenocarcinoma Ic 9 1.5
18. Endometrioid cystadenocarcinoma IIb 14 0.9
19. Endometrioid cystadenocarcinoma Ia 18 5.4
20. Endometrioid cystadenocarcinoma Ia 22 0.9
2 1 . Endometrioid cystadenocarcinoma IIb 22 1.6
22 . Endometrioid cystadenocarcinoma IIIb 22 11.8
23. Endometrioid cystadenocarcinoma Ic 30 0.5
24. Clear cell cystadenocarcinoma IIIa 14 2.5
25. Clear cell cystadenocarcinoma Ia 23 0.1
doi:10.1371/journal.pone.0010293.t001
12.3 and 16.6 mmol/L. These values are in the same range as the 
NAA concentration in oCF of serous EOTs.
Discussion
This study shows that NAA is present in low micromolar 
concentration in all ovarian cyst fluid samples. Serous ovarian 
tumors however, contained a significantly higher oCF concentra­
tion of NAA than mucinous, endometrioid and clear cell tumors. 
The median NAA concentration in serous EOTs was 5.1 mmol/L, 
whereas one third of all samples contained an NAA concentration 
above 10.0 mmol/L. The NAA concentration in serous EOTs was
5 to 50 fold higher than the NAA concentration previously found
Table 2. NAA (mmol/L) in ovarian cyst fluid and ascites.
Patient no. H istology Subtype NAA (mmol/L) cyst fluid NAA (mmol/L) ascites
1 . Malignant Serous 4.9 5.0
2 . Malignant Serous 1.2 1.0
3. Malignant Serous - 24.5
4. Malignant Mucinous 0.8 0.4
5. Malignant Clear cell 0.1 0.6
doi:10.1371/journal.pone.0010293.t002
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in CSF, serum and amniotic fluid of healthy individuals.[7] Some 
serous EOTs contained an NAA oCF concentration in the same 
range as found in the extracellular space of the human brain and 
all serous tumors by far exceeded the NAA concentration in 
human serum.[1] Interestingly, the oCF NAA concentration in 
serous EOTs did not differ between benign, borderline and 
malignant histology, indicating that NAA expression might be 
specific for EOTs with a serous cell differentiation.
NAA was present in fluid of mucinous EOTs and hepatic cysts 
as well but this concentration was comparable to the NAA 
concentration in human serum.[7] Serous and mucinous EOTs 
could almost perfectly be distinguished when using an NAA cut-off 
value of 1.1 mmol/L. Most endometrioid and clear cell carcinomas
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Figure 2. NAA (mmol/L) in cyst fluid of patients with serous (n = 36), mucinous (n = 23), endometrioid (n = 8) and clear cell (n = 2) EOT, 
patients with hepatic cysts (n = 10) and hydrosalpinges (n = 2), presented on a logarithm ic scale.
doi:10.1371/journal.pone.0010293.g002
contained an NAA concentration which was comparable to the 
concentration of NAA in human serum or CFS. However, in some 
of these samples a higher NAA concentration was found. This may 
be explained by the common presence of cells of different ovarian 
cancer subtypes within a single tumor. In general, approximately 
6% of the ovarian carcinomas can be classified as mixed type 
ovarian carcinomas (at least two histologically distinctive elements 
are present in at least 10% of the tumor surface).[13] However, 
more frequently, ovarian carcinomas are found to exist of a main 
subtype and a small percentage of cells representing a different 
histology.[13] Our findings indicate that the brain amino acid 
NAA is predominantly present in oCF of serous EOTs and 
therefore, seems to be characteristic for this specific histological 
subtype. Therefore, NAA analysis in oCF might be used to 
diagnostically distinguish between serous EOTs and other EOT 
subtypes.
Although 90% of the ovarian tumors derive from the epithelial 
surface of the ovary, EOTs are not a single disease entity, but 
instead comprise a heterogeneous group of tumors.[14,15] These 
tumors are classified according to their pattern of histological 
differentiation.[16] Serous tumors bear strong resemblance to the 
normal cells lining the fallopian tube. Mucinous tumors show 
strong similarity to epithelium of the intestine and endometrioid 
and clear cell tumors are morphologically identical to cells of the 
lining of the endometrium.[17] Interestingly, the normal cellular 
lining of the ovary does not resemble any of these organs. The high 
concentration of NAA found in oCF of serous EOT, independent 
of their malignant potential, might be due to their specific cellular 
differentiation pattern, which resembles the lining of the fallopian 
tube and differs from the other histological subtypes. This finding 
is supported by our observation of similar high amounts of NAA 
found in hydrosalpingeal fluid, which is a fluid accumulation in the 
fallopian tube due to distal obstruction.[12] However, the question 
remains why NAA is found in such high amounts in oCF of serous
EOT as its presence and function have been specifically been 
assigned to the human brain.
So far, the brain is the only organ where NAA synthesis has been 
demonstrated in humans. However, two animal studies have 
revealed extra neuronal NAA synthesis.[8,9] In the first study, 
NAA has been demonstrated in ocular fluid, the lens and retina of 
fish and mammals.[9] Despite a low micromolar serum concentra­
tion of NAA, high amounts of NAA and all components required for 
synthesis of NAA were present in the eye of these animals. In the 
present study, the NAA concentration in all serum samples was 
within the normal range of 0.17-0.84 mmol/L [7] and did not vary 
between patients with different histological subtypes. The NAA 
concentration in oCF of serous tumors was mostly 10 to 50 fold 
higher than the normal serum NAA concentration. As serum and 
oCF samples were simultaneously taken, our data suggest a local 
NAA synthesis in the tumor or a pump mechanism which actively 
pumps NAA from the serum into the oCF. In other ovarian tumor 
subtypes, serum and cyst fluid concentration of NAA was 
comparable, which might suggest that local NAA production 
primarily occurs in EOTs ofserous histology. Peripheral synthesis of 
NAA also has been described for peritoneal mast cells of the rat. [8] 
Release of NAA from mast cells was found to occur rapidly when 
degranulating agents were used.[8] Although this finding has not yet 
been confirmed in humans, release of NAA from mast cells might be 
an alternative explanation for the high NAA concentration in oCF 
and ascites. It has been demonstrated that mast cells are frequently 
present in stroma tissue of several cancer types, including ovarian 
carcinomas.[18,19] A growing number of studies has shown that the 
mast cell count correlates with tumor stage, tumor invasiveness and 
prognosis.[18] In addition, mast cells are known to be present in 
ascites of cancer patients as well.[20] However, we found that a high 
concentration of NAA in oCF and ascites was characteristic for 
patients with serous EOTs, independent of the malignant potential 
of the tumor. Mast cells in ovarian stromal tissue have been
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10293
NAA in Ovarian Tumors
demonstrated in all histological subtypes of EOTs and numbers 
were found to be increased in carcinomas compared to their normal 
tissue counterparts.[19,21] Therefore, we consider a local NAA 
production in serous EOTs as the most likely explanation for the 
higher concentration of NAA in serous oCF samples.
Recently, Baslow proposed that the NAA cycle itself might serve 
as a neuronal mechanism to remove large amounts of water 
generated during action potential development.[1,5] To prevent 
swelling of neurons, this metabolic water has to be eliminated, 
which has been to occur energy driven and against a water 
gradient. If the NAA system would function as a so called 
molecular water pump, as a result of the enzymatic hydrolysis of 
NAA in the oligodendrocytes, its obligated water can be released. 
This would subsequently result in a hypoosmotic extracellular 
space, from which it can be removed from the brain.[5] Canavan 
Disease (CD) is a genetic disorder which causes NAA accumula­
tion in the brain due to a deficiency in the NAA-degrading enzyme 
aspartoacylase.[2] The disease is characterized by the buildup of 
excessive fluid within the myelin lamellae, in swollen astrocytes 
and in extracellular fluid vacuoles.[5] Baslow suggests that this 
accumulation of NAA is responsible for the macrocephaly in CD.
EOTs, benign as well as malignant, mostly appear as large cystic 
masses, sometimes diagnosed with a diameter up to 50 cm. In 
mucinous tumors, cysts are thought to be formed by mucus 
producing epithelial cells. Mucus is known to contain large amounts 
of glycoprotein with a high carbohydrate content.[22] In contrast, 
serous EOT are usually filled with a clear and watery fluid, [12] but 
the mechanism responsible for serous cyst formation is still unknown. 
On the basis of our findings and taking into account the proposed 
role of NAA in body water management [1,5], we hypothesize that 
high amounts of NAA in oCF of serous EOTs may be related to 
accumulation of water in the tumor and may contribute to cyst 
formation. In addition, this proposed mechanism might also be 
involved in the formation of ascites in patients with serous 
adenocarcinomas and in accumulation of hydrosalpingeal fluid. 
However, as yet there is no confirmatory study in literature to prove 
the role of NAA in water management. Therefore, our findings 
might contribute to the understanding of the so far undefined 
function of NAA. More evidence is required for the putative role of 
serous epithelial cells in NAA synthesis and cyst formation.
Methods
Ethics statement
The ovarian cyst fluid (oCF) samples involved in this study were 
obtained after surgical removal of the ovarian tumor. The hepatic 
and hydrosalpingeal biomaterial and ascites involved in this study 
were collected through a clinical (therapeutic) procedure. The 
informed consent for these procedures was obtained verbally in 
presence of a witness and documented in the patient’s medical 
record. As part of the procedure we asked the patient for 
permission to use the residual biomedical waste (i.e. cyst fluid) for 
research purposes. The Institutional Review Board from the 
Radboud University Nijmegen Medical Center (RUNMC) 
considers that the use of residual biomedical waste presents no 
more than minimal risk or harm to the participants and involves 
no procedures for which written consent is normally required 
outside of the research context. The study was approved by the 
ethical board of the RUNMC (file number AMO 09/107).
Patients and ovarian cyst fluid
Ovarian cyst fluid (oCF) was retrieved from our Radboud 
University Nijmegen Medical Center (RUNMC) biobank. This 
biobank contains samples of patients who underwent primary
surgery for with an ovarian tumor at the RUNMC in the period 
between 1998 and 2008. Samples were collected by aseptic fine 
needle aspiration at the Department of Pathology immediately 
after surgical removal of the ovarian tumor. After cooled transport 
to the laboratory, all samples were centrifuged at 3000 xg for
10 minutes and the supernatant was stored at —35°C in small 
portions until use. For the purpose of this study, 80 oCF samples 
were randomly selected from our biobank. Complete histopath- 
ological reports and slides of all patients were reviewed for correct 
histopathological diagnosis by one pathologist (JB), specialized in 
gynecological pathology. Eleven oCF samples were excluded 
because the ovarian tumor was non-epithelial or not primary 
ovarian-derived. Histopathological diagnosis of the remaining 69 
EOTs revealed 36 serous, 23 mucinous, 8 endometrioid and 2 
clear cell tumors. Of these 69 EOTs, 25 were malignant, 8 tumors 
were of borderline malignancy and 36 tumors were benign 
(Table 3). Of 7 patients with an EOT preoperative serum was 
collected as well. These samples were obtained from 3 patients 
with serous tumors (2 malignant and one borderline), 2 patients 
with mucinous tumors (malignant and borderline), a patient with 
an endometrioid carcinoma and a patient with a clear cell 
carcinoma. Of 5 patients, ascites samples were obtained during 
primary surgery. One ascites sample was obtained without the 
availability of an oCF sample. Informed consent was obtained 
from all participants.
Hepatic cyst fluid
Cyst fluid from 45 patients with polycystic liver disease (PCLD) 
was obtained between 2002 and 2008 by percutaneous cyst 
aspiration or laparoscopic cyst fenestration and stored in aliquots 
at —20°C. For this study, we randomly selected hepatic cyst fluid 
samples of 10 patients. None of these patients had a previous 
diagnosis of carcinoma. The samples were centrifuged at 3000 xg 
for 10 minutes.
Hydrosalpingeal fluid
Hydrosalpingeal fluid accumulates in the Fallopian tube due to 
distal obstruction. This fluid was collected from 2 salpinges of 1 
patient undergoing laparoscopic salpingectomy for presence of 
bilateral hydrosalpinges. Aspiration of the fluid was performed 
during surgery by fine needle aspiration before the fallopian tubes 
were excised. Verbal consent was obtained and documented in the
Table 3. Overview of biological fluid samples grouped by 
origin.
Histopathology
Origin of biological fluid n Malignant Borderline Benign
Ovarian cyst 69 25 8 36
Serous subtype 36 9 3 24
Mucinous subtype 23 6 5 12
Endometrioid subtype 8 8 0 0
Clear cell subtype 2 2 0 0
Hepatic cyst 10 0 0 10
Ascites 5 5 0 0
Hydrosalpinx 2 0 0 2
Serum 7 5 2 0
doi:10.1371/journal.pone.0010293.t003
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patient’s file. The samples were centrifuged at 3000 xg for
10 minutes and the supernatant was stored at —35°C until use.
N-acetyl-L-aspartic acid (NAA)
NAA (mmol/L) was measured using a modified stable isotope 
dilution Gas Chromatography-Mass Spectrometry (GC-MS) 
method essentially as described by Jakobs et al. [7] In short, 
1 nmol [D3]-NAA was added as internal standard to 100 ml of CF. 
This was also added to aqueous standards. The samples were 
acidified with 30 ml HCL (6 mol/l) to pH <2 and saturated with 
NaCl. Thereafter, the sample was extracted four times with 2 ml 
of an ethylacetate-2-propanol mixture (v/v 10:1). The collected 
organic fractions were dried by anhydrous Na2SO4 and 
subsequently evaporated to dryness at 40°C under a gentle stream 
of N2. NAA was converted to its di-isopropyl derivative by adding 
500 ml isopropanol and 10 ml 6 mol/l HCl and subsequent heating 
for 1 hour at 120°C. An aliquot of 1 ml of this mixture was 
analysed by GC-MS. GC-MS analysis of 1 ml of this mixture was 
performed on an Agilent Technologies GC system 6890N with a 
5973 MS detector. The gas chromatographic separation was 
achieved on a CPSil-88 capillary fused silica column 
(25 mx0.25 mm, df=0.28 mm, Chrompack Int., Middelburg, 
The Netherlands). Helium was used as carrier gas. The oven 
temperature was kept at 80°C for 1 min and then raised to 240°C 
at a rate of 30°C/min. The interface and source temperatures 
were kept at 240°C. The inter-assay variation for this method was 
8% (n = 5) and the intra-assay variation was 2% (n=10). All 
samples were analysed within the linear range of the standard 
curve (0-20 nmol/L). If concentrations were above the standard 
curve, samples were diluted with water.
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Clinicopathological characteristics of patients with an 
EOT
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